| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry - paraffin section; human; loading ...; fig 3d
- immunoprecipitation; human; loading ...; fig 1b
- western blot; human; loading ...; fig 4a
| Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23:1055-1062 pubmed publisher |
- western blot; human; loading ...; fig s5b
| Tyler D, Vappiani J, Cañeque T, Lam E, Ward A, Gilan O, et al. Click chemistry enables preclinical evaluation of targeted epigenetic therapies. Science. 2017;356:1397-1401 pubmed publisher |
- immunohistochemistry; human; 1:100; fig s2
| Tögel L, Nightingale R, Chueh A, Jayachandran A, Tran H, Phesse T, et al. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Mol Cancer Ther. 2016;15:1217-26 pubmed publisher |
- western blot; mouse; fig 1
| Nakagawa A, Adams C, Huang Y, Hamarneh S, Liu W, Von Alt K, et al. Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomains. Sci Rep. 2016;6:20390 pubmed publisher |
- western blot; human; fig 3
| Shu S, Lin C, He H, Witwicki R, Tabassum D, Roberts J, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413-417 pubmed publisher |
| Kang M, Kim J, Ryu E, Ha N, Hwang S, Kim B, et al. PCNA Unloading Is Negatively Regulated by BET Proteins. Cell Rep. 2019;29:4632-4645.e5 pubmed publisher |
| Huang Y, Mouttet B, Warnatz H, Risch T, Rietmann F, Frommelt F, et al. The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. Cancer Cell. 2019;36:630-644.e9 pubmed publisher |
| Stock C, Michaeloudes C, Leoni P, Durham A, Mumby S, Wells A, et al. Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation. Biomed Res Int. 2019;2019:1484736 pubmed publisher |
| Wang B, Fan P, Zhao J, Wu H, Jin X, Wu H. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2018;37:224 pubmed publisher |
| Qin C, Hu Y, Zhou B, Fernandez Salas E, Yang C, Liu L, et al. Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. J Med Chem. 2018;61:6685-6704 pubmed publisher |
| Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez Salas E, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018;61:462-481 pubmed publisher |
| Janouskova H, El Tekle G, Bellini E, Udeshi N, Rinaldi A, Ulbricht A, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23:1046-1054 pubmed publisher |
| Gates L, Shi J, Rohira A, Feng Q, Zhu B, Bedford M, et al. Acetylation on histone H3 lysine 9 mediates a switch from transcription initiation to elongation. J Biol Chem. 2017;292:14456-14472 pubmed publisher |
| Keck K, Moquin S, He A, Fernandez S, Somberg J, Liu S, et al. Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps. J Biol Chem. 2017;292:13284-13295 pubmed publisher |
| Sakamaki J, Wilkinson S, Hahn M, Tasdemir N, O Prey J, Clark W, et al. Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function. Mol Cell. 2017;66:517-532.e9 pubmed publisher |
